TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A MedPage Today roundup published October 23, 2026, highlighted studies finding that up to 84% of prescriptions for certain oral blood cancer drugs were initially denied, body-composition changes may precede pancreatic cancer diagnosis, and fake citations appeared in thousands of cancer journal articles. The findings come from separate studies and do not establish that fat changes can diagnose cancer or explain why insurers denied prescriptions.
A cancer research roundup published October 23 highlighted three separate findings: up to 84% of prescriptions for specialty oral blood cancer drugs were initially denied in a nationwide claims study; changes in body fat may appear before pancreatic cancer is diagnosed; and a review found fake citations in thousands of cancer journal articles. The findings concern different issues—access to treatment, possible early indicators, and research integrity—and do not establish a diagnostic test or explain the reasons for the denials.
The prescription-denial figure came from a nationwide study of claims submitted to Medicare and private insurers, according to the roundup, which cited the Journal of Clinical Oncology. The study reported that as many as 84% of prescriptions for specialty oral cancer drugs used for blood cancers were denied at first. The summary does not specify which drugs or patient groups accounted for the highest rates, how often denials were overturned, or the reasons insurers gave.
In a separate finding attributed to the Mayo Clinic, detectable changes in body composition—particularly decreases in visceral and subcutaneous fat—may precede a pancreatic cancer diagnosis by up to three years. The roundup describes a potential association, not a validated screening method. It also cites a review by researchers at Queensland University of Technology that examined 33,000 cancer-journal articles and found fake citations in 4,000 articles attributed to so-called paper mills.
The roundup included other developments, including early laboratory research into statins and chemotherapy resistance in pancreatic cancer, and a rapid-access cancer care program associated with earlier treatment for patients at socioeconomic risk of poor outcomes. These items are distinct from the three central findings and have different levels of evidence; the source summary does not provide detailed methods or outcome data for them.
Access, Early Signals and Research Trust
The reported initial denial rate points to a potential barrier between prescribing and receiving oral cancer treatment. These drugs may be taken outside a hospital, but the roundup does not report how many patients ultimately obtained the medication or whether delays affected their care. Those details matter when interpreting what an initial denial means for patients.
The body-composition finding could help researchers investigate whether changes occur before pancreatic cancer becomes clinically apparent. However, a possible signal is not the same as a reliable test: the supplied summary gives no information on accuracy, false positives, or whether acting on the changes improves outcomes. The citation review, meanwhile, raises concerns about the reliability of published cancer research. Fake references can complicate the work of readers and researchers trying to verify claims, but the summary does not say whether the affected articles were corrected or withdrawn.
cancer patient medication organizer pill box
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Separate Research Findings
The source is a short MedPage Today cancer-news roundup, not a single study linking insurance decisions, body fat and fabricated references. It summarizes findings reported by several organizations and publications. The claims-denial figure is attributed to a study in the Journal of Clinical Oncology; the body-composition observation is attributed to Mayo Clinic; and the citation findings are attributed to Queensland University of Technology.
That distinction matters: each result has its own methods and limitations, which cannot be assessed from the brief roundup alone. In particular, the phrase “up to 84%” describes the reported upper figure for initial denials, not a rate for every prescription or insurer. Likewise, “may precede” describes a possible timing relationship and does not establish that fat loss causes pancreatic cancer or predicts it in any individual.
Study Details Still Needed
The roundup does not provide the study periods, sample sizes, or detailed methods for the claims analysis and body-composition research. It is unclear how denial rates varied by insurer, drug, or patient characteristics, how many denials were later reversed, and whether the reported body-fat changes were specific enough to distinguish people who would develop pancreatic cancer from those who would not.
For the citation review, the summary does not identify the articles, explain how researchers classified a citation as fake, or state what action journals have taken. It also gives no follow-up on corrections or retractions. The findings should therefore be treated as a report of research conclusions, not as a complete account of their implications.
Full Studies and Follow-Up
Readers seeking to assess the findings will need the full study papers and their methods, along with any subsequent reporting from the researchers, journals, and insurers. Follow-up on the claims research could clarify whether initial denials were overturned and whether patients experienced treatment delays. Further validation would be needed before body-composition changes could be considered useful for screening or clinical decisions.
The roundup does not announce a specific next milestone for any of the three findings. Journal responses to the reported fake citations, and any corrections to affected papers, also remain unreported in the supplied material.
Key Questions
What does the 84% figure mean?
It is the reported upper rate of initial denials for prescriptions for specialty oral drugs used for blood cancers in a nationwide claims study. The summary does not say what share of denied prescriptions was later approved.
Can body-fat changes diagnose pancreatic cancer?
No diagnostic use is established by the information provided. The report says changes in visceral and subcutaneous fat may precede diagnosis by up to three years; it does not provide test accuracy or recommend using these changes for screening.
What did the review find about fake citations?
A review of 33,000 articles in cancer journals reportedly identified fake citations in 4,000 articles. The roundup does not detail how the citations were assessed or what journals did afterward.
Are the three findings part of one study?
No. The roundup groups together separate findings on insurance claims, body composition and research citations. Each has a different source and should be interpreted on its own.
Source: rss
Evergreen bestsellers Picks
bestsellers
As an affiliate, we earn on qualifying purchases.
